+0.02 (+1.44%)
Symbol AVRO
Price $1.41
Beta 1.278
Volume Avg. 0.33M
Market Cap 62.849M
Shares () -
52 Week Range 0.57-1.93
1y Target Est -
DCF Unlevered AVRO DCF ->
DCF Levered AVRO LDCF ->
ROE 61.54% Strong Buy
ROA 49.18% Strong Buy
Operating Margin -
Debt / Equity 1.70% Neutral
P/E -14.10 Strong Sell
P/B 0.61 Buy


Consensus EPS

Upgrades & Downgrades

Latest AVRO news

Mr. Erik John Ostrowski M.B.A.
NASDAQ Global Select

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.